Predictive Oncology released FY2025 Q2 earnings on August 13, 2025 (EST), actual revenue USD 2.682 K (forecast USD 1.5 M), actual EPS USD -3.4507

Brief Summary

Predictive Oncology’s Q2 2025 financial results show a revenue of $2,682 with an EPS of -$3.4507, significantly missing the expected revenue of $1.5 million.

Impact of The News

The financial briefing indicates that Predictive Oncology has severely underperformed in its Q2 2025 financial results.

• Revenue Expectations: The company reported actual revenue of $2,682, missing the anticipated revenue of $1.5 million by a substantial margin.
• EPS Performance: The EPS is reported at -$3.4507, implying that the company is operating at a loss. This presents a stark contrast to other tech companies, such as Figma and Micron, which have shown significant revenue growth and market expectation beating performances .

Position Relative to Peers:

• Compared to peers like Adobe, Oracle, and Micron, Predictive Oncology is in a more challenging position. Other companies have shown growth in revenue and EPS, even surpassing market expectations . Predictive Oncology, however, has not met even the basic revenue expectations.

Business Status and Trends:

• Current Business Status: The financial performance suggests operational difficulties and possible liquidity issues which could impact Predictive Oncology’s ability to innovate and compete effectively in its market segment.
• Future Trends: Given the significant underperformance, the company may need to reassess its business strategy, reduce operational costs, or seek new investment to enhance its product offerings and market position.

In conclusion, Predictive Oncology’s financial results highlight key challenges in achieving expected market performance, indicating potential difficulties in sustaining future growth without strategic changes.